By Mauro Orru Novartis's generics-and-biosimilars division Sandoz was granted marketing authorization from the European Commission to commercialize and.
By Adria Calatayud Novartis's Sandoz generic-drugs unit has received approval from the U.S. Food and Drug Administration for biosimilar medicine Tyruko to.
By Adam L. Cataldo Shares of Design Therapeutics dropped in post-market trading after the drug developer said patients in a phase 1 clinical study developed.
By Will Feuer Design Therapeutics shares plunged, notching a new all-time low on the Nasdaq, after the drug developer said patients in a phase 1 clinical.
By Josh Beckerman Shares of biotechnology company Alector rose 31% to $8.66 after it reported second-quarter results and updates for its pharmaceutical.